Exosomal non-coding RNAs: key molecules in the diagnosis and treatment of coronary artery disease
Ma C., Gao X., Li K., Liu Y., He Y., Zhang Y.
Narrative Review on Chronic Kidney Disease, Cardiovascular Disease, published in PeerJ (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- PeerJ (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40520644
- PMCID
- PMC12164816
- DOI
- 10.7717/peerj.19352
Abstract (original English)
Coronary artery disease (CAD) is a leading cause of mortality worldwide. As aging populations grow and lifestyle changes, the incidence of CAD is escalating. Traditional biomarkers for CAD diagnosis, such as creatine kinase-muscle brain (CK-MB), troponins, and n-terminal pro b-type natriuretic peptide (NT-proBNP), are influenced by age, sex, the presence of chest pain, and renal function levels. However, since these biomarkers are also detected in many other diseases such as heart failure, chronic renal failure, pulmonary embolism, or septic shock, explore and identification of novel unique biomarkers for CAD are of clinical significance. Exosomes containing non-coding RNAs, proteins, and lipids can serve as biomarkers and regulators for regulate various biological processes. Exosomal non-coding RNAs have been identified as risk factors for CAD and pivotal elements in cellular functions, making them significant candidates for CAD diagnosis and prognosis. This review elaborates on the current understandings of CAD, highlights the important roles of exosomal non-coding RNAs in CAD diagnosis and treatment, and concludes with future perspectives.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review
Systematic Review on Chronic Kidney Disease, published in Ren Fail (2026) — summary generated from the PubMed abstract.
- 2026
Ren Fail - Level AMeta-analysisEurope PMC
Meta-analysis study of the therapeutic impact of Mesenchymal stem cells derived exosomes for chronic kidney diseases
Meta-analysis on Chronic Kidney Disease, published in Biochem Biophys Rep (2025) — summary generated from the PubMed abstract.
- 2025
Biochem Biophys Rep2 citations - Level ASystematic ReviewPubMed
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Systematic Review with a reported sample of 953 on Osteoarthritis, Chronic Kidney Disease, Scar, Autoimmune Research, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
- n = 953
Int J Mol Sci2 citations - Level ASystematic ReviewEurope PMC
Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024
Systematic Review on Chronic Kidney Disease, Acute Kidney Injury, published in Front Immunol (2025) — summary generated from the PubMed abstract.
- 2025
Front Immunol2 citations - Level AMeta-analysisEurope PMC
Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Meta-analysis on Chronic Kidney Disease, Chronic Inflammation, published in Cells (2025) — summary generated from the PubMed abstract.
- 2025
Cells - Level AMeta-analysisEurope PMC
Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis
Meta-analysis on Chronic Kidney Disease, Acute Kidney Injury, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol1 citations